XHKG2192
Market cap936mUSD
Dec 23, Last price
9.93HKD
1D
1.95%
1Q
26.02%
IPO
-66.96%
Name
Medlive Technology Co Ltd
Chart & Performance
P/E
28.22
P/S
16.59
EPS
0.33
Div Yield, %
1.71%
Shrs. gr., 5y
1.25%
Rev. gr., 5y
37.62%
Revenues
412m
+31.19%
Net income
242m
+106.53%
CFO
102m
+31.97%
Dividend
Oct 22, 20240.132 HKD/sh
Earnings
May 23, 2025
Profile
Medlive Technology Co., Ltd., together with its subsidiaries, operates an online professional physician platform in Mainland China and internationally. Its precision marketing and corporate solution provides full service on its one-site platform, which includes project management, clinical monitoring, clinical data management, biostatistics, protocol design, medical monitoring, patient recruitment, and supporting system, as well as digital market research, electronic data capture, real-world studies, and application software development services. The company's medical knowledge solution offers medical education and clinical decision support, including licensing software to physicians, other registered users, such as other healthcare professionals and pharmaceutical companies. Its intelligent patient management solution provides chronic disease management services, comprising online patient consultation, prescription services, and patient management through Internet hospital; and condition-specific patient education services, which includes content development, application software development, and other related services. The company was formerly known as Kingyee Co., Limited and changed its name to Medlive Technology Co., Ltd. in 2021. Medlive Technology Co., Ltd. was founded in 1996 and is headquartered in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 412,004 31.19% | 314,054 10.41% | 284,440 33.21% | |||
Cost of revenue | 337,928 | 298,886 | 236,705 | |||
Unusual Expense (Income) | ||||||
NOPBT | 74,076 | 15,168 | 47,735 | |||
NOPBT Margin | 17.98% | 4.83% | 16.78% | |||
Operating Taxes | 1,372 | 8,616 | 24,682 | |||
Tax Rate | 1.85% | 56.80% | 51.71% | |||
NOPAT | 72,704 | 6,552 | 23,053 | |||
Net income | 242,301 106.53% | 117,321 188.85% | 40,616 -52.33% | |||
Dividends | (124,687) | (12,133) | (92,000) | |||
Dividend yield | 2.02% | 0.19% | 0.53% | |||
Proceeds from repurchase of equity | 5,261 | 5,014 | 4,033,146 | |||
BB yield | -0.09% | -0.08% | -23.32% | |||
| Debt | ||||||
Debt current | 4,549 | 5,136 | 4,207 | |||
Long-term debt | 11,835 | 17,388 | 22,131 | |||
Deferred revenue | ||||||
Other long-term liabilities | 55,199 | 27,803 | 18,491 | |||
Net debt | (4,426,885) | (4,257,533) | (3,853,109) | |||
| Cash flow | ||||||
Cash from operating activities | 101,866 | 77,189 | 44,433 | |||
CAPEX | (750) | (7,488) | (1,968) | |||
Cash from investing activities | (634,945) | (3,585,555) | (50,541) | |||
Cash from financing activities | (133,130) | (22,380) | 3,792,050 | |||
FCF | 96,210 | (3,336) | 1,361 | |||
| Balance | ||||||
Cash | 4,400,895 | 4,216,904 | 3,908,744 | |||
Long term investments | 42,374 | 63,153 | (29,297) | |||
Excess cash | 4,422,669 | 4,264,354 | 3,865,225 | |||
Stockholders' equity | 741,546 | 514,344 | 99,164 | |||
Invested Capital | 3,967,047 | 3,921,425 | 3,873,111 | |||
ROIC | 1.84% | 0.17% | 1.19% | |||
ROCE | 1.57% | 0.34% | 1.20% | |||
| EV | ||||||
Common stock shares outstanding | 734,583 | 736,502 | 635,801 | |||
Price | 8.42 -1.29% | 8.53 -68.64% | 27.20 | |||
Market cap | 6,185,189 -1.55% | 6,282,360 -63.67% | 17,293,795 | |||
EV | 1,806,137 | 2,055,718 | 13,503,184 | |||
EBITDA | 83,447 | 24,155 | 53,884 | |||
EV/EBITDA | 21.64 | 85.11 | 250.60 | |||
Interest | 361 | 531 | 535 | |||
Interest/NOPBT | 0.49% | 3.50% | 1.12% | |||